Search results for "Adverse effect"

showing 10 items of 1065 documents

Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-contro…

2020

AbstractBACKGROUNDTreatment of severe Corona Virus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.METHODSIn this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned to receive either UC-MSCs (4 × 107 cells per infusion) or placebo on day 0, 3, and 6. The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28. Other imaging outcomes, 6-minute walk test, maximum vital capaci…

medicine.medical_specialtyLungbusiness.industryIncidence (epidemiology)PlaceboGastroenterologyUmbilical cordmedicine.anatomical_structureInternal medicineDiffusing capacityClinical endpointmedicineStem cellAdverse effectbusiness
researchProduct

Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis.

2015

IMPORTANCE: Randomized clinical trials (RCTs) and meta-analyses of sublingual immunotherapy (SLIT) for the treatment of seasonal allergic rhinoconjunctivitis (SARC) have shown a modest clinical benefit compared with placebo. Furthermore, indirect comparison by meta-analyses showed that subcutaneous immunotherapy is more effective than SLIT. Despite these data, SLIT has become the most prescribed treatment of SARC in Europe in recent years, and it was approved by the US Food and Drug Administration for the treatment of SARC to grass pollen in the United States on April 1, 2014. OBJECTIVE: To assess the efficacy and safety of the grass pollen sublingual tablets licensed as drugs in the treatm…

medicine.medical_specialtyMEDLINECochrane LibraryPlaceboPlant Extractlaw.inventionRandomized controlled triallawInternal medicineInternal MedicinemedicineClinical endpointmedia_common.cataloged_instanceHumansEuropean unionAdverse effectmedia_commonConjunctivitis AllergicSublingual Immunotherapybusiness.industryPlant ExtractsAllergenMedicine (all)Rhinitis Allergic SeasonalAllergensAntigens PlantMeta-analysisImmunologybusinessHumanJAMA internal medicine
researchProduct

Oral health effects of botulinum toxin treatment for drooling:a systematic review

2020

Background Drooling is a major morbidity in several neurological diseases. Intraglandular botulinum neurotoxin (BoNT) injections have been used to manage this condition. However, by decreasing salivary flow, BoNT injections may result in an increased risk of caries and other oral adverse effects. In this study, we aimed to assess whether, in patients with drooling, intraglandular BoNT injections are associated with increased dental caries development, modifications on salivary composition (oral pH, buffering capacity and osmolality) and cariogenic bacterial load. Material and Methods We performed a systematic review, searching PubMed, CENTRAL, Web of Science, and Scopus for all experimental…

medicine.medical_specialtyMEDLINEOral HealthReviewOral healthDental CariesDroolinglaw.inventionameloblastomaRandomized controlled triallawInternal medicinemedicineHumansBotulinum Toxins Type AAdverse effectGeneral DentistryUNESCO:CIENCIAS MÉDICASbusiness.industryCerebral Palsyodontogenic tumorSialorrheaMedically compromised patients in Dentistryameloblastoma recurrenceBotulinum toxinOtorhinolaryngologyNeuromuscular AgentsSurgeryObservational studymedicine.symptombusinessoral pathologyBiomedical sciencesmedicine.drug
researchProduct

Hyperpigmentation of hard palate induced by chloroquine therapy

2017

The antimalarials are one of the most commonly prescribed drugs for conditions such as lupus erythematosus and rheumatoid arthritis, and the side effects, though infrequent, are well known. The antimalarial agent chloroquine diphosphate usually causes pigmentary changes in the oral mucosa characterized by a bluish-grey to black discolorations mainly in the hard palate. Considering only the hard palate hyperpigmentation caused by chloroquine, to the best of our knowledge, only 13 cases have been reported in the English language literature. We described an additional case of palate hyperpigmentation related to the chronic use of chloroquine diphosphate in a 60-year-old Mexican woman. Although…

medicine.medical_specialtyMedication historyCase Report03 medical and health sciences0302 clinical medicineChloroquinemedicineAntimalarial AgentOral mucosaAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]HyperpigmentationDermatologymedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisUNESCO::CIENCIAS MÉDICASHard palatemedicine.symptombusinessmedicine.drug
researchProduct

Unexpected adverse effect of metyrapone: A case report

2018

medicine.medical_specialtyMetyraponebusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismmedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyEndocrinologyInternal medicinemedicineAdverse effectbusinessRhabdomyolysis030217 neurology & neurosurgerymedicine.drugClinical Endocrinology
researchProduct

Differences in patients and lesion and procedure characteristics depending on the age of the coronary chronic total occlusion

2018

Introduction: Whether duration of chronic total occlusion (CTO) affects lesion and procedural characteristics remains largely unknown. Aim: To investigate whether CTO duration influences lesion characteristics and revascularization success. Material and methods: EuroCTO Registry data on patients who had CTO percutaneous coronary intervention between January 2015 and April 2017 were analyzed. Three groups were created based on occlusion age: 3 to 6 months (n = 1415), 7 to 12 months (n = 973), > 12 months (n = 1656). Results: Patients with greater CTO duration were older (63.0 (56.0–70.0); 63.0 (56.0–71.0); 66.0 (59.0–73.0) years respectively; p < 0.001), had more 3-vessel disease (32.2…

medicine.medical_specialtyMultivariate analysismedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyRevascularizationlesion characteristicsPercutaneous coronary intervention.Lesion03 medical and health sciences0302 clinical medicineInternal medicineOcclusionMedicine030212 general & internal medicineLesion characteristicAdverse effectchronic total occlusionOriginal Paperbusiness.industrypercutaneous coronary interventionlcsh:RPercutaneous coronary interventionCollateral circulationmedicine.anatomical_structureCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessArtery
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study

2014

ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on gastric cancer cells, whereas it is only present on a fraction of healthy stomach cells. This may reduce the risk of target-related side effects. Single-agent IMAB362 appears safe in patients with advanced gastro-esophageal cancer (GEC) based on data from a phase I trial. Methods: This international, multicenter, non-randomized phase IIa study (NCT01197885) investigated the efficacy and safety of repeated doses of IMAB362 (300 and 600 mg/m2) in patients with metastatic, refractory/recurrent, CLDN18.2-positive GEC (i.e. cancer of the stomach, the lower esophagus and th…

medicine.medical_specialtyNauseabusiness.industryPhases of clinical researchHematologyEsophageal cancermedicine.diseaseChemotherapy regimenGastroenterologyOncologyResponse Evaluation Criteria in Solid TumorsInternal medicineAnesthesiamedicineVomitingProgression-free survivalmedicine.symptomAdverse effectbusinessAnnals of Oncology
researchProduct

Adverse Events and Unsuccessful Intubation Attempts Are Frequent During Neonatal Nasotracheal Intubations.

2021

Background: Intubation of neonates is difficult and hazardous. Factors associated with procedure-related adverse events and unsuccessful intubation attempts are insufficiently evaluated, especially during neonatal nasotracheal intubations.Objective: Aim of this study was to determine the frequency of tracheal intubation–associated events (TIAEs) during neonatal nasotracheal intubations and to identify factors associated with TIAEs and unsuccessful intubation attempts in our neonatal unit.Methods: This was a prospective, single-site, observational study from May 2017 to November 2019, performed at a tertiary care neonatal intensive care unit in a German academic teaching hospital. All endotr…

medicine.medical_specialtyNeonatal intensive care unitintubation attemptmedicine.medical_treatmentadverse eventEndotracheal intubation610 Medicine & healthTertiary carePediatricsRJ1-570intubationTeaching hospital03 medical and health sciencesnasotracheal0302 clinical medicine030225 pediatricsmedicineIntubation030212 general & internal medicineNeonatal nursesAdverse effect610 Medicine & healthOriginal Researchbusiness.industryPediatrics Perinatology and Child HealthEmergency medicineObservational studyneonatebusinessFrontiers in pediatrics
researchProduct

Antimicrobial therapy in neonatal intensive care unit

2015

Severe infections represent the main cause of neonatal mortality accounting for more than one million neonatal deaths worldwide every year. Antibiotics are the most commonly prescribed medications in neonatal intensive care units (NICUs) and in industrialized countries about 1% of neonates are exposed to antibiotic therapy. Sepsis has often nonspecific signs and symptoms and empiric antimicrobial therapy is promptly initiated in high risk of sepsis or symptomatic infants. However continued use of empiric broad-spectrum antibiotic treatment in the setting of negative cultures especially in preterm infants may not be harmless. The benefits of antibiotic therapy when indicated are clearly enor…

medicine.medical_specialtyNeonatal intensive care unitmedicine.drug_classAntibioticsReviewGlobal HealthInfant Newborn DiseasesSepsisIntensive Care Units NeonatalIntensive caremedicineHumansAntibiotic prophylaxisAdverse effectIntensive care medicineEmpiric therapyAntibiotic stewardshipNeonatal sepsisbusiness.industryInfant NewbornAntibioticAntibiotic ProphylaxisNewbornmedicine.diseaseAnti-Bacterial AgentsAntibiotic; Antibiotic stewardship; Empiric therapy; Neonatal sepsis; Newborn; Resistant bacteria; Pediatrics Perinatology and Child HealthPediatrics Perinatology and Child HealthNeonatal sepsisNeonatal sepsiResistant bacteriabusinessEmpiric therapyItalian Journal of Pediatrics
researchProduct